Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
Recruiting · NCT06846606 · Registry updated 2026-09-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, acute myeloid leukemia, bone marrow disorder, hematologic disorder, leukemia, myelodysplastic syndrome, myeloid leukemia, neoplasm | Recruiting | Phase 1 | 2026-09-14 | NCT06846606 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Auron Therapeutics, Inc. | 1 |
9 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| City of Hope National Medical Center | Duarte | United States | 68 |
| H Lee Moffitt Cancer Center and Research Institute | Tampa | United States | 11 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 60 |
| Ohio State University, The James Comprehensive Cancer | Columbus | United States | 1 |
| Roswell Park Comprehensive Cancer Center | Buffalo | United States | 32 |
| Sarah Cannon Center for Blood Cancer at TriStar Centennia | Nashville | United States | 1 |
| University of North Carolina At Chapel Hill | Chapel Hill | United States | 50 |
| University of Texas MD Anderson Cancer Center | Houston | United States | 192 |
| UPENN Perelman Center for Advanced Medicine | Philadelphia | United States | 1 |